Long-COVID in Children and Adolescents: A Systematic

Review and Meta-analyses

Sandra Lopez-Leon MD, PhD^{1,2,}, Talia Wegman-Ostrosky MD, PhD³, Norma Cipatli Ayuzo del Valle MD⁴, Carol Perelman, BSc⁵, Rosalinda Sepulveda MD PhD⁶, Paulina A Rebolledo, MD, MSc^{7,8}, Angelica Cuapio MD, Dr.Med⁹, Sonia Villapol, PhD^{10,11*}

¹Quantitative Safety & Epidemiology, Novartis Pharmaceuticals, New Jersey, U.S.A. ORCID <u>0000-0001-7504-3441</u>

²Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers University, New Jersey, U.S.A.

³Instituto Nacional de Cancerología, Subdirección de Investigación básica, Ciudad de México, México, ORCID <u>0000-0002-3207-6697</u>

⁴Departamento de Pediatría, Tecnologico de Monterrey, Mexico. ORCID <u>0000-0002-8110-</u> <u>3532</u>

⁵Universidad Nacional Autónoma de México (UNAM), SOMEDICyT, RedMPC, México. ORCID <u>0000-0002-0111-1154</u>

⁶Harvard T.H. Chan School of Public Health Boston, Massachusetts, USA. ORCID <u>0000-0003-</u> <u>1146-9552</u>

⁷Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.

⁸Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, U.S.A. ORCID <u>0000-0002-9808-063X</u>

⁹Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden. ORCID <u>0000-0002-9451-1914</u>

¹⁰Department of Neurosurgery, Center for Neuroregeneration, Houston Methodist Research Institute, Houston, Texas, U.S.A.

¹¹Department of Neuroscience in Neurological Surgery, Weill Cornell Medical College, New York, U.S.A. ORCID <u>0000-0002-6174-4113</u>

***Correspondence and request for materials should be addressed to** Sonia Villapol, Ph.D. Current address; Department of Neurosurgery, Houston Methodist Research Institute, 6670 Bertner Avenue, R10-117, Houston, 77030, TX. *email: svillapol@houstonmethodist.org*.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

The objective of this systematic review and meta-analyses is to estimate the prevalence of long-COVID in children and adolescents and to present the full spectrum of symptoms present after acute COVID-19. We have used PubMed and Embase to identify observational studies published before February 10th, 2022 that included a minimum of 30 patients with ages ranging from 0 to 18 years that met the National Institute for Healthcare Excellence (NICE) definition of long-COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥12 weeks) symptoms. Random-effects meta-analyses were performed using the MetaXL software to estimate the pooled prevalence with a 95% confidence interval (CI). Heterogeneity was assessed using l² statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed (registration PROSPERO CRD42021275408). The literature search yielded 8,373 publications, of which 21 studies met the inclusion criteria, and a total of 80.071 children and adolescents were included. The prevalence of long-COVID was 25.24%, and the most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), and sleep disorders (8.42%). Children infected by SARS-CoV-2 had a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever compared to controls. Limitations of the studies analyzed include lack of standardized definitions, recall, selection, misclassification, nonresponse and/or loss of follow-up, and a high level of heterogeneity.

Keywords: Long-COVID, post-acute sequelae of SARS-CoV-2 (PASC), pediatric long hauler, post-COVID children, COVID-19 kids, COVID-19 syndrome

INTRODUCTION

It has been two years since the coronavirus disease 2019 (COVID-19) pandemic was first declared. Consequently, millions of cases and thousands of deaths have been reported worldwide¹. Still, treatments have been developed rapidly during this time, and effective vaccines have been widely administered to the population, both children and adults, protecting millions from severe disease and death ². Until now, the focus was primarily aimed at the acute phase of the disease. However, many individuals experience debilitating COVID-19 symptoms months later, requiring additional medical attention and follow-up.

Severe COVID-19 is less common in children than in adults³; however, two long-term consequences occur following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children: multisystem inflammatory syndrome (MIS-C) and long-COVID. Both consequences can even appear in asymptomatic patients⁴. MIS-C is a condition where different body parts become inflamed⁴, it occurs in less than 0.01% of children infected and requires intensive care support in 68% of cases⁵. Long-COVID is a heterogeneous multisystemic condition for which there is still no precise definition and includes signs and symptoms that persist, develop, or fluctuate after SARS-CoV-2 infection. In October 2021, the WHO proposed a clinical definition for post-COVID-19 through a Delphi consensus stating it generally occurs three months from the onset of COVID-19, with symptoms lasting at least two months and cannot be explained by an alternative diagnosis⁶. On February 2nd, 2022, the National Institute for Health and Care Excellence (NICE) published a guideline defining long-COVID as signs and symptoms that continue or develop after acute COVID-19. This includes ongoing symptomatic COVID-19 (from 4 to 12 weeks) and post-COVID-19 syndrome (12 weeks or more)⁷. Other organizations, such as the National Institutes of Health (N.I.H.), also define long-COVID as post-acute symptoms after four weeks⁸. Many authors have used the following terms interchangeably when referring to long-COVID: long-haulers, COVID-long, post-acute sequelae of COVID-19 (PASC), post-COVID, COVID syndrome, and long-COVID. In the present study, we will use the generic definition from NICE and N.I.H., referring to long-COVID.

To date, most of the published research on long-COVID primarily focuses on adult populations, and there is limited information on pediatric populations^{9,10}. The most recent meta-analysis has studied the long-COVID symptoms and their prevalence, risk factors, type, and duration, including studies up to July 2021, encompassing 23,141 children and young people⁹. The most common symptoms were fatigue 47%, dyspnea 43%, and headache 35%. In addition, compared to controls, the prevalence of cognitive difficulties, headache, loss of smell, sore throat, and sore eyes was statistically higher⁹, however, due to the lack of data, this study could only compute the pooled prevalence for 10 symptoms. To date, the potential range of signs and symptoms and their frequency of occurrence in children and adolescents

3

remains unclear¹¹. There is a need to create awareness among parents, physicians, and researchers on the afflictions following COVID-19 infection and the health system to better understand the sequelae to provide targeted medical attention and treatment. This systematic review and meta-analyses aim to estimate the prevalence of long-COVID in children and adolescents and identify the full spectrum of symptoms.

METHODS

Data sources and search strategy.

This systematic review and meta-analyses were reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline¹². It examines the prevalence of long-COVID signs and symptoms in children under the age of 18 with a diagnosed case of COVID-19 (confirmed via real-time reverse transcription-polymerase chain reaction (rt-PCR), antigen or antibody (or serology) tests). To achieve this, two independent investigators (T.W.O and S.L.L.) searched PubMed and Embase to identify studies that met the following criteria: 1) a minimum of 30 patients, 2) ages ranged from 0 to 18 years, 3) studies published in English, 4) published before February 10th, 2022, and 5) meet the NICE definition of long-COVID, 6) excluding cohorts of children composed of exclusively pre-existing chronic diseases, or exclusively of MIS-C in children, and 7) excluding references of editorials, reviews, and commentaries (Figure 1).




Figure 1.

The search terms used to identify publications discussing long-COVID in children were: (COVID-19 OR COVID OR SARSCOV-2 OR coronavirus OR "long-COVID" OR "post COVID") AND (PASC OR haulers OR lingering OR "post-acute" OR persistent OR convalescent OR convalescence OR sequelae OR post-viral) AND (pediatric OR kids OR young OR infant OR children OR adolescents). Given that MedLine was included in the PubMed search, we excluded articles from MedLine in the Embase search along with those not related to COVID-19. Observational studies, including cohorts and cross-sectional studies, were analyzed only when the cases (numerator) were part of a COVID-19 cohort (denominator). Titles, abstracts, and full texts of articles were independently screened. Disagreement on including a full-text article was discussed among all the authors. We developed and registered a review protocol (PROSPERO registration number: CRD42021275408).

Screening and data extraction

Data were extracted by four authors (A.C., C.A., P.R., R.S.) and Quality-Controlled (QCed) data by two authors (T.W.O., C.P.). Discrepancies were discussed with a third author. The descriptive variables extracted were country, study design, period of study, collection mode, follow-up time, the severity of COVID-19, sample size, COVID-19 diagnosis, age, percentage of males, outcomes, and names used to describe the long-term effects of COVID-19.

Statistical analysis

Random-effects meta-analyses were performed for symptoms reported in two or more studies using MetaXL software to estimate the pooled prevalence, which uses a double arcsine transformation¹³. Prevalence (presented as percentages) with 95% confidence intervals (C.I.s) was estimated. Numerators represented the number of children with long-COVID, and denominators described the total number of children with acute COVID-19 (with and without long-term effects). To compare cases and controls adjusted for confounders, we used Review Manager (RevMan) software 5.4 to estimate the Odds Ratios (O.R.s)¹⁴. A p-value < 0.05 was considered statistically significant. Given the heterogeneity expected, a random-effects model was employed using the I² statistics. Values of 25, 50, and 75% for I² represented low, medium, and high heterogeneity, respectively. Studies with high precision plotted near the average, and those with low precision are speeded evenly on both sides of the average. Deviation from a funnel shape distribution this shape can indicate publication bias¹⁴. The quality control of the study was assessed using the QCed data. The MetaXL Guidelines describe and recommend this index, which evaluates the quality of studies assessing prevalence.

5

RESULTS

General characteristics of studies

The title and abstract of 8,373 publications were screened. After duplicates were removed, the search identified 68 publications after screening titles and abstracts, and 47 were excluded because they did not fulfill the inclusion criteria. A total of 21 studies were selected for the analyses (Figure 1). The general study characteristics are shown in Table 1. Different authors have used the terms "Post-acute COVID," "long-COVID," "Persistent COVID," and "Persistent COVID Symptoms" as synonyms. Most of the studies assessed pre-specified symptoms included in a questionnaire. 18 of the selected studies come from European cohorts (Denmark, Russia, Italy, Germany, Tukey, Latvia, UK, France, Sweden, and Switzerland), one from Iran, one from Brazil, and one from Australia. The studies by Kikkenborg¹⁵ and Borch¹⁶ included an overlapping population (Denmark), as did Roge¹⁷ and Smane¹⁸ (Latvia). To ensure that no overlapping data were included, only the study with the largest sample size was included to estimate long-COVID and for outcomes reported in both studies. Still, several outcomes were only presented in one of the studies, therefore both studies were included in the overall meta-analysis. Four studies included only hospitalized patients, and the rest included all COVID-19 severities (asymptomatic, mild, moderate, and severe). The number of patients included in the studies ranged from 53 to 57,763, and ages ranged from 0 to 18 years. A total of 80,071 children and adolescents with COVID-19 were included in the meta-analyses. We identified more than 40 long-term clinical manifestations associated with COVID-19 in the literature reviewed (Table 2).

Table 1. General Characteristics of Studies.

Author	Countr y	Study Design	Collection mode	Follow-up time included in M.A.	Severity %	N cases (denominat or)	N controls	COVID-19 diagnoses	Control definition	Age range	Sex % Male	Term
Asadi-Pooya ¹⁹	Iran	CSS	Phone (questionnaire)	>3 months	Hospitalized	58	NA	PCR	NA	6 to 17	48%	Long COVID
Blankenburg ²⁰	Germa ny	CSS	Schools (survey)	>3 months	NR	188	1365	lgG	lgG negative	14 to 16	45%	Long-COVID19
Borch ¹⁶	Denma rk	RCS	Electronic (questionnaire)	>1 month	Asymptoma tic	15,041	15,080	PCR	Not a PCR positive in the past	0 to 17	NR	Long COVID
Buonsenso ²¹	Italy	CSS	Phone or inpatient (questionnaire)	>4 months	All severities	129	NA	PCR	NA	>18	52%	Long COVID
Erol ²²	Turkey	RCS	Clinical	5.6 months average	All severities	121	*95	"tested positive"	Not having contact with someone with COVID- 19.19	>18	54%	Long Covid
Fink ²³	Brasil	PCS	Outpatient and inpatients validated instruments and clinic	4.4 months average	Symptomati c (Outpatient and inpatients)	53	*52	PCR or antibody	*Negative PCR or antibody	8 to 18	42%	Post-COVID-19/ long term PASC/ Long COVID-19
Kikkenborg Berg*	Denma rk	CSS	Electronic (survey)	2 months	All severities	6,630	21,640	Tested positive	Not tested positive	15 to 18	58%	Long COVID
Knoke ²⁴	Germa ny	CSS	Outpatient (questionnaire and pulmonary function testing)	2.6 months average	Asymptoma tic	73	45	PCR or antibody	No antibodies, 31% other infection	5 to 18	48%	Long term COVID /persistent symptoms
Matteudi ²⁵	France	PCS	Phone (questionnaire)	10 to 13 months	All severities	137	NA	PCR	NA	0 to 15	N.R.	Long-term consequences/persisting symptoms/ Long COVID
Miller ²⁶	U.K.	PCS	Electronic (weekly survey)	≥ 1 month	NR	174	NA	"nasal swab"	NA	≤17	45%	Persistent symptoms/ long COVID

Molteni ²⁷	U.K.	PCS	Electronic App	>2 months	NR	1734	NA	PCR IgG	NA	5 to 17	50%	Persistent symptoms
Osmanov ²⁸	Russia	PCS	Phone (SARIC COVID-19 Health and Wellbeing Follow-Up Survey for Children)	>5months	Hospitalized	518	NA	PCR	NA	3 to 15	47%	Long Term /long covid/ persistent symtoms
Radtke ²⁹	Switzerl and	PCS	Online (questionnaire)	>3 months	Asymptoma tic and mild	109	1246	Serology	Seronegativ e	6 to 16	46%	Long COVID/ SARS- Cov-2 postviral syndromes
Roge ¹⁷	Latvia	PCS and RCS	Phone (questionnaire)	1 to 6 months	All severities	236	142	PCR or seroconversio n	Other infections	0 to 18	55.50%	Persistent Symptoms/ long COVID/ long-term consequences/ long- lasting symptoms/ long- term persistent symptoms/ late sequelae of COVID-19
Roessler ³⁰	Germa ny	RCS	Health Insurance data	≥3 months	All severities	57,763	*288,815	Laboratory virus detection	Non- laboratory virus detection	0 to 17	51.30%	Post COVID19/ Long term health sequelae/ post-acute COVID-19 syndrome / post COVID- 19 condition
Rusetsky ³¹	Russia	PCS	Phone	At 2 months	Hospitalized	79	NA	PCR	NA	9.5-16.3	47%	Persistent
Say ³²	Australi a	PCS	Clinical	3 to 6 months	All severities	151	NA	PCR	NA	0 to 12	58%	Post-acute COVID-19
Smane* 18	Latvia	RCS	Clinical	1 to 3 months	Hospitalized	92	N.A.	N.R.	NA	8 to 15	61%	Post-acute COVID/ long- term consequences
Stephenson ³³	U.K.	PCS	Paper questionnaire	At 3 months	Non- hospitalized	3065	3739	PCR	PCR negative	11 to 17	37%	Long COVID/ post- COVID symptomatology/ long haulers/ post-acue COVID syndrome)
Sterky ³⁴	Swede n	PCS	Phone questionnaire	Median 7.3, range 4.1 to 10.8 months	Hospitalized	55	NA	PCR	NA	0 to 18	58%	Persistent/ Long COVID/ Long term health issues
Zavala ³⁵	U.K.	RCS	Paper questionnaire	At 1 month	All severities	387	472	PCR	PCR negative	0 to 16	51%	Persistent

Controls: did not present numbers, therefore it could not be used CSS= cross-sectional study, DM=diabetes mellitus, NA= not applicable, NR= not reported, MA= meta-analysis M=months, PCS= prospective cohort study, RCS=retrospective cohort study * Part of the population duplicated.

Meta-analyses of the prevalence of long-COVID

The prevalence of long-COVID in minors, as defined by the presence of one or more symptoms more than 4 weeks following a SARS-CoV-2 infection, was 25.24% (95% CI, 18.17-33.02, I^2 99.61%) (Figure 2 and Figure 3). For hospitalized patients, the prevalence of long-COVID was 29.19% (95% CI, 17.83-41.98, I^2 80.84%). The most common symptoms and percentage of prevalence associated were mood symptoms (e.g., sadness, tension, anger, depression, and anxiety) (16.50%; 95% CI, 7.37-28.15, I^2 97.49%), fatigue (9.66%; 95% CI, 4.45-16.46, I^2 99.12%), sleep disorders (e.g., insomnia, hypersomnia, and poor sleep quality) (8.42%; 95% CI, 3.41-15.20, I^2 93.49%); headache (7.84%; 95% CI, 4.04-12.70, I^2 98.49%), respiratory symptoms (7.62%; 95% CI, 2.08-15.78, I^2 99.15%), sputum production or nasal congestion (7.53%; 95% CI, 3.78-12.36, I^2 0%), cognitive symptoms (e.g., less concentration, learning difficulties, confusion, and memory loss) (6.27%; 95% CI, 4.46-8.35, I^2 91.32%), loss of appetite (6.07%; 95% CI, 3.95-8.59, I^2 93.54%), exercise intolerance (5.73%; 95% CI, 0.00-19.38, I^2 87.77%), and altered smell (e.g., hyposmia, anosmia, hypersomnia, parosmia, and phantom smell) (5.60%; 95% CI, 3.13-8.69, I^2 97.11%). All other symptoms had less than 5.00% prevalence (Table 2, Figure 2, and Supplementary Figure 1).






Table 2. Pooled prevalence of symptoms in children and adolescents.

CLINICAL MANIFESTATIONS	Studies	Cases	Sample Size	l²	Prevalence % (95%Cl)
Mood (sad, tense, angry, depression, anxiety)	5	730	6047	97.49	16.50 (7.37-28.15)
Fatigue	16	3015	21592	99.12	9.66 (4.45-16.46)
Sleep disorder (insomnia, hypersomnia, poor sleep quality)	8	153	1592	93.49	8.42 (3.41-15.20)
Headache	13	1875	21108	98.49	7.84 (4.04-12.70)
Respiratory symptoms	9	1387	19013	99.15	7.62 (2.08-15.78)
Sputum/nasal congestion	2	11	150	0	7.53 (3.78-12.36)
Cognition (less concentration, learning difficulties, confusion, memory loss)	11	1223	19803	91.31	6.27 (4.46-8.35)
Loss of appetite	5	747	9379	93.54	6.07 (3.95-8.59)
Exercise intolerance	2	8	150	87.77	5.73 (0.00-19.38)

Altered smell (hyposmia, anosmia, hypersomnia, parosmia, phantom smell)	10	2048	20818	97.11	5.60 (3.13-8.69)
Hyperhidrosis	2	36	738	93.59	4.66 (0.00-13.85)
Chest pain	6	467	18777	98.24	4.62 (1.52-9.11)
Dizziness	6	791	9340	97.77	4.40 (1.50-8.59)
Rhinorrhea	5	65	1032	94.10	4.15 (0.10-11.89)
Cough	10	570	19688	86.60	3.80 (2.61-5.19)
Myalgia/arthralgia	9	547	19564	93.67	3.76 (2.18-5.75)
Body weight changes	3	30	865	96.82	3.99 (0.00-14.00)
Altered taste	5	1273	16005	92.23	3.65 (1.35-6.92)
Otalgia (tinnitus, earache, vertigo)	3	207	3773	92.65	3.41 (0.84-7.35)
Ophthalmologic (conjuntivitis, dry eye, problems seeing/blurred vision, photophobia, pain)	6	384	9411	91.07	3.00 (1.66-4.69)

Abdominal pain	8	277	9611	73.94	2.91 (2.04-3.92)
Dermatologic (dry skin, itchy skin, rashes, hives)	6	218	9322	78.68	2.61 (1.73-3.67)
Sore Throat	6	401	10311	98.46	2.47 (0.25-6.23)
Chest tightness	5	293	6319	92.81	2.45 (0.58-5.35)
Variations in heart rate	2	18	729	88.54	2.29 (0.00-7.36)
Constipation	3	20	1101	81.01	2.05 (0.39-4.75)
Dysphonia	2	62	3301	0	1.89 (1.45-2.38)
Fever	5	167	18709	96.27	1.87 (0.50-3.99)
Musculoskeletal other	3	383	15618	87.72	1.72 (0.41-3.78)
Diarrhea	7	218	19337	81.01	1.68 (0.63-3.18)
Vomiting/nausea	5	260	16144	24.91	1.53 (1.09-2.03)
Changes in menstruation	3	10	866	43.98	1.27 (0.38-2.60)
Palpitations	4	165	6178	93.55	1.27 (0.00-3.83)

Hair loss	3	16	1209	80.31	1.17 (0.10-3.10)
Neurological abnormalities (pins and needles, tremor, numbness)	3	8	997	0	0.86 (0.37-1.55)
Urinary symptoms	3	6	1060	0	0.63 (0.23-1.21)
Dysphagia	3	5	1207	0	0.46 (0.14-0.93)
Speech Disturbances	3	5	1197	40.41	0.44 (0.05-1.10)




Figure 3.

Meta-analyses of O.R.s (cases vs. controls)

It was only possible to perform meta-analyses of O.R.s comparing cases and controls for 13 symptoms (mood, fatigue, headache, dyspnea, concentration problems, anosmia/ageusia,

loss of appetite, rhinitis, myalgia/arthralgia, cough, fever, sore throat, and nausea/vomiting) (Figure 4). When compared to controls, children with long-COVID had a higher risk of persistent dyspnea (OR:2.69; 95%CI, 2.30-3.14, I²0%), anosmia/ageusia (OR:10.68; 95% CI, 2.48, 46.03, I²0%), and/or fever (OR:2.23; 95% CI, 1.2-4.07, I²12%). There was significant heterogeneity for 4 out of the 13 meta-analyses (Figure 4). The controls were chosen in a very different way among studies, which might have introduced significant heterogeneity. The following were the different definitions of controls, minors with: 1) other infections (e.g., common cold, pharyngotonsillitis, gastrointestinal, urinary tract infections, pneumonia of bacteria or unknown origin)¹⁷; 2) no antibodies testing²⁴ mixed with other infections¹⁷; 3) a negative antibody test²⁹, 4) a negative rtPCR test among symptomatic minors³⁵; and 5) minors who did not have a positive test recorded in the database¹⁵ (Supplementary Figure 2). The adjustments among studies also varied. Several studies adjusted their OR by age, sex, ethnicity, socioeconomic status, and comorbidities ³⁵. However, age and sex¹⁵ only adjusted for sex, only for age¹⁷, did not adjust, or by OR without adjusting previous conditions²⁴.

Study or Subgroup	Odds Ratio Random, 95% Cl	Odds Ratio Random, 95% Cl
Mood Kikkenborg Berg Age 15-18 (vs. no postive test)	0.82 [0.74, 0.91]	
Roge age 0-18 (vs other infections)	16.00 [4.60, 55.65]	
Zavala age 0-16 (vs PCR neg symptomatic)	3.94 [1.16, 13.38]	
Subtotal (95% CI)	3.46 [0.51, 23.27]	
Heterogeneity: Tau ² = 2.59; Chi ² = 27.80, df = 2 (P < Test for overall effect: Z = 1.28 (P = 0.20)	0.00001); I* = 93%	
Fatigue		
Kikkenborg Berg Age 15-18 (vs. no postive test)	1.06 [0.98, 1.15]	-
Knoke age 5-18(vs no antibodies /other infecction) Roge age 0-18 (vs other infections)	3.19 [0.70, 14.54] 8.70 [2.50, 30.28]	
Subtotal (95% CI)	2.79 [0.66, 11.75]	
Heterogeneity: Tau ² = 1.32; Chi ² = 12.89, df = 2 (P = 12.89 , df = 2 (P = 12.89) Test for overall effect: Z = 1.40 (P = 0.16)	0.002); l² = 84%	
Headache		
Kikkenborg Berg Age 15-18 (vs. no postive test) Knoke age 5-18(vs no antibodies /other infecction)	1.22 [1.10, 1.35] 1.44 [0.38, 5.46]	
Roge age 0-18 (vs other infections)	12.90 [1.70, 97.89]	
Subtotal (95% CI)	1.95 [0.69, 5.52]	
Heterogeneity: Tau ² = 0.53; Chi ² = 5.24, df = 2 (P = 0 Fest for overall effect: Z = 1.25 (P = 0.21)	.07); l² = 62%	
Dyspnea		
Kikkenborg Berg Age 15-18 (vs. no postive test) Knoke age 5-18(vs no antibodies /other infecction)	2.70 [2.31, 3.16] 1.63 [0.15, 17.71]	
Roge age 0-18 (vs other infections)	2.10 [0.20, 22.05]	_
Subtotal (95% CI)	2.69 [2.30, 3.14]	◆
Heterogeneity: Tau² = 0.00; Chi² = 0.21, df = 2 (P = 0 Test for overall effect: Z = 12.49 (P < 0.00001)	.90); I* = 0%	
Concentration problems		
Kikkenborg Berg Age 15-18 (vs. no postive test) Roge age 0-18 (vs other infections)	1.04 [0.97, 1.12] 13.60 [1.70, 108.81]	Ť
Roge age 0-18 (vs other infections) Subtotal (95% CI)	3.02 [0.25, 36.19]	
Heterogeneity: Tau ² = 2.74; Chi ² = 5.86, df = 1 (P = 0 Test for overall effect: Z = 0.87 (P = 0.38)		
Anosmia/ Ageusia		
Roge age 0-18 (vs other infections)	11.20 [1.40, 89.61]	
Zavala age 0-16 (vs PCR neg symptomatic) Subtotal (95% CI)	10.20 [1.31, 79.41] 10.68 [2.48, 46.03]	
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 0.00$, $df = 1$ (P = 0 Test for overall effect: Z = 3.18 (P = 0.001)		
Loss of appetite		
Kikkenborg Berg Age 15-18 (vs. no postive test)	1.15 [1.02, 1.30]	<u>+</u>
Roge age 0-18 (vs other infections) Subtotal (95% CI)	2.50 [0.90, 6.95] 1.43 [0.72, 2.82]	
Heterogeneity: Tau ² = 0.16; Chi ² = 2.19, df = 1 (P = 0		
Test for overall effect: Z = 1.02 (P = 0.31)		
Rhinitis Knoke age 5-18(vs no antibodies /other infecction)	0.14 [0.03, 0.65]	← →────
Roge age 0-18 (vs other infections)	2.60 [1.30, 5.20]	
Subtotal (95% CI)	0.66 [0.04, 11.44]	
Heterogeneity: Tau ² = 3.90 ; Chi ² = 11.49 , df = 1 (P = Test for overall effect: Z = 0.29 (P = 0.77)	0.0007); l² = 91%	
Myalgia/ arthralgia		
Kikkenborg Berg Age 15-18 (vs. no postive test) Knoke age 5-18(vs no antibodies /other infecction)	1.09 [0.91, 1.31]	
Subtotal (95% CI)	1.24 [0.33, 4.66] 1.09 [0.91, 1.31]	•
Heterogeneity: Tau ² = 0.00; Chi ² = 0.04, df = 1 (P = 0 Test for overall effect: Z = 0.97 (P = 0.33)		-
Cough		
Kikkenborg Berg Age 15-18 (vs. no postive test)	1.63 [1.43, 1.86]	
Knoke age 5-18(vs no antibodies /other infecction) Roge age 0-18 (vs other infections)	0.24 [0.06, 0.96] 1.90 [0.90, 4.01]	•
Roge age 0-18 (vs other infections) Subtotal (95% CI)	1.90 [0.90, 4.01] 1.20 [0.55, 2.58]	
Heterogeneity: Tau ² = 0.32; Chi ² = 7.46, df = 2 (P = 0 Test for overall effect: Z = 0.45 (P = 0.65)		-
Fever Fever		
Kikkenborg Berg Age 15-18 (vs. no postive test)	1.53 [0.74, 3.16]	+
Knoke age 5-18(vs no antibodies /other infecction) Roge age 0-18 (vs other infections)	2.69 [0.67, 10.80] 4.00 [1.40, 11.43]	
Roge age 0-18 (vs other infections) Subtotal (95% CI)	4.00 [1.40, 11.43] 2.23 [1.22, 4.07]	
Heterogeneity: Tau ² = 0.04; Chi ² = 2.28, df = 2 (P = 0 Fest for overall effect: Z = 2.61 (P = 0.009)		
Sore throat		
	1.59 [1.21, 2.09]	
Knoke age 5-18(vs no antibodies /other infecction)	0.44 [0.12, 1.61]	
Knoke age 5-18(vs no antibodies /other infecction) Roge age 0-18 (vs other infections)	0.44 [0.12, 1.81] 3.50 [0.70, 17.50] 1.34 [0.54, 3.27]	
Knoke age 5-18(vs no antibodies /other infecction) Roge age 0-18 (vs other infections) Subtotal (95% Cl) Heterogeneity: Tau ² = 0.37; Chi ² = 4.62, df = 2 (P = 0	3.50 [0.70, 17.50] 1.34 [0.54, 3.27]	
Knoke age 5-18(vs no antibodies /other infecction) Roge age 0-18 (vs other infections) Subtotal (95% Cl) Heterogeneity: Tau ² = 0.37; Chi ² = 4.62, df = 2 (P = 0	3.50 [0.70, 17.50] 1.34 [0.54, 3.27]	
Knoke age 5-18(vs no antibodies /other infection) Roge age 0-18 (vs other infections) Subtotal (95% CI) Heterogeneity: Tau ² = 0.37; Chi ² = 4.62, df = 2 (P = 0 Test for overall effect: Z = 0.63 (P = 0.53) Nausea/ Vomiting Kikkenborg Berg Age 15-18 (vs. no postive test)	3.50 [0.70, 17.50] 1.34 [0.54, 3.27] .10); ² = 57% 1.09 [0.92, 1.29]	-
Knoke age 5-18(vs no antibodies /other infecction) Roge age 0-18 (vs other infections) Subtotal (95% Cl) Heterogeneity: Tau ² = 0.37; Chi ² = 4.62, df = 2 (P = 0 Test for overall effect: Z = 0.63 (P = 0.53) Nausea/ Vomiting Kikkenborg Berg Age 15-18 (vs. no postive test) Roge age 0-18 (vs other infections)	3.50 [0.70, 17.50] 1.34 [0.54, 3.27] .10); I ² = 57% 1.09 [0.92, 1.29] 6.20 [0.60, 64.06]	
Knoke age 5-18(vs no antibodies /other infecction) Roge age 0-18 (vs other infections) Subtotal (95% CI) Heterogeneity: Tau ² = 0.37; Chi ² = 4.62, df = 2 (P = 0 Fest for overall effect: Z = 0.63 (P = 0.53) Nausea/ Vomiting Kikkenborg Berg Age 15-18 (vs. no postive test) Roge age 0-18 (vs other infections) Subtotal (95% CI) Heterogeneity: Tau ² = 0.80; Chi ² = 2.12, df = 1 (P = 0) Comparison of the subtotal (95% CI) Heterogeneity: Tau ² = 0.80; Chi ² = 2.12, df = 1 (P = 0) Comparison of the subtotal (95% CI)	3.50 [0.70, 17.50] 1.34 [0.54, 3.27] .10); I ² = 57% 1.09 [0.92, 1.29] 6.20 [0.60, 64.06] 1.73 [0.38, 7.81]	
Knoke age 5-18(vs no antibodies /other infecction) Xoge age 0-18 (vs other infections) Subtotal (95% CI) Heterogeneity: Tau ² = 0.37; Chi ² = 4.62, df = 2 (P = 0 Fest for overall effect: Z = 0.63 (P = 0.53) Nausea/ Vomiting Kikkenborg Berg Age 15-18 (vs. no postive test) Xoge age 0-18 (vs other infections) Subtotal (95% CI) Heterogeneity: Tau ² = 0.80; Chi ² = 2.12, df = 1 (P = 0)	3.50 [0.70, 17.50] 1.34 [0.54, 3.27] .10); I ² = 57% 1.09 [0.92, 1.29] 6.20 [0.60, 64.06] 1.73 [0.38, 7.81]	
Kikkenborg Berg Age 15-18 (vs. no postive test) Knoke age 5-18(vs no antibodies /other infecction) Roge age 0-18 (vs other infections) Subtotal (95% CI) Heterogeneity: Tau ² = 0.37; Chi ² = 4.62, df = 2 (P = 0 Test for overall effect: Z = 0.63 (P = 0.53) Nausea/ Vomiting Kikkenborg Berg Age 15-18 (vs. no postive test) Roge age 0-18 (vs other infections) Subtotal (95% CI) Heterogeneity: Tau ² = 0.80; Chi ² = 2.12, df = 1 (P = 0 Test for overall effect: Z = 0.71 (P = 0.47)	3.50 [0.70, 17.50] 1.34 [0.54, 3.27] .10); I ² = 57% 1.09 [0.92, 1.29] 6.20 [0.60, 64.06] 1.73 [0.38, 7.81]	

Figure 4.

Other Findings

The prevalence of symptoms over the course of long-COVID for cases and controls is shown in Supplementary Figure 2. Given the heterogeneity in the definition of controls and the low number of subjects, no formal statistical comparison was done for the crude prevalence. The symptoms that were presented in a single study and, therefore, unable to be incorporated into the meta-analyses, include: orthostatic intolerance, cold hands/feet, chapped lips, adenopathy, fainting, twitching of fingers and toes, chills, swollen toes/fingers, and hallucinations.

One study reported statistically significant differences between clinical cases and controls for systolic blood pressure, left ventricular ejection fraction, relative myocardial wall thickness, and tricuspid annular plane systolic excursion²². However, given that these variables were only evaluated in this study, we could not perform a meta-analysis for these outcomes. Studies included in the meta-analyses evaluated whether certain variables increased the risk of long-COVID and found that age, sex, severe acute-COVID-19, obesity, allergic disease, and long-term health conditions^{19,26,28,36}. Further, two of the studies evaluated the duration of symptoms. A study from Denmark reported that symptoms resolved in a minimum of 54–75% of minors within 1–5 months¹⁶. Another from England, reported that 4.4% of children still had symptoms four weeks after COVID-19 onset, which decreased to 1.8% at 8 or more weeks²⁷.

Quality of studies

Regarding the quality of studies, all had a score of 7 or more (Supplementary Table 1). Table 3 presents a list of methodological strengths or limitations for each study. All studies included laboratory-confirmed COVID-19 infection, rt-PCR, antigen, or antibody test. Two-thirds of the studies included over 100 children. Six meta-analyses had low heterogeneity (I²<25%) for the following symptoms: vomiting and nausea, nasal congestion, dysphonia, urinary problems, neurological abnormalities, and dysphagia. Three meta-analyses had medium heterogeneity for the following symptoms: abdominal pain, changes in menstruation, and speech disturbances. All other meta-analyses had high heterogeneity (I²>75%). Given that very few studies by the different variables (e.g., age, sex, country, or past comorbidities), there were not enough studies that included this information to evaluate where the heterogeneity originated.

DISCUSSION

The prevalence of long-COVID in children and adolescents was 25.24%. The five most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), sleep disorders (8.42%), headache (7.84%), and respiratory symptoms (7.62%). It was only possible to perform meta-analyses of ORs comparing cases and controls for 13 symptoms, with a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever. Studies have shown that the pandemic has profoundly impacted society by affecting children's development through isolation, poverty, food insecurity, loss of parents and caregivers, loss of time in education, and increased stress³⁷. COVID-19 pandemic has initiated an explosion of future mental illnesses³⁸, affecting both society as a whole and those who recover from long-COVID. The presence of these symptoms in the general population, regardless of COVID-19 status, has been coined long-Pandemic Syndrome²⁰.

Interestingly, many of the symptoms identified in these meta-analyses associated to long-COVID, such as mood, fatigue, sleep disorders, orthostatic intolerance, decreased concentration, confusion, memory loss, balance problems, exercise intolerance, hyperhidrosis, blurred vision, body temperature dysregulation, dysfunction on heart, rate variability and palpitations, constipation or diarrhea, and dysphagia, are commonly present in dysautonomia³⁹. Dysautonomia is a dysfunction of the sympathetic and/or parasympathetic autonomic nervous system. However, it remains unclear whether dysautonomia may be a direct result of the SARS-CoV-2 infection, interaction with other viruses, or immune-mediated processes such as cytokines, which are known mediators of the inflammatory response⁴⁰⁻⁴³. Moreover, the constellation of symptoms because of long-COVID can vary from patient to patient, fluctuating in their frequency and severity⁴⁴. Like adults, the pediatric population's risk factors associated with long-COVID are older age, female gender, severe COVID-19, overweight/obesity, comorbid allergic diseases, and other long-term co-morbidities. Protective factors leading to milder severity and duration of COVID-19, and possibly also long-COVID in children, include fewer comorbidities, strong innate immune responses, reduced expression of angiotensin-converting enzyme-2 (ACE2) receptors, and active thymic function, which leads to the increased presence and decreased depletion of T cells. Further protections include a range of environmental or non-inheritable factors such as vaccines, past infections, nutrition, and/or the gut microbiome^{19,26,28,36,45}. Concerning age, most of the studies did not discriminate between children (<12-year-old) and adolescents. Given that the risk increases with age, there is a need for future studies to stratify by age. In addition, the evaluation of self-reporting symptoms can be significantly biased by age as younger children might not be able to express

their emotional and functional status relevant to post-COVID-19 adequately. Further studies targeting age groups are required.

The prevalence of symptoms is highly dependent on how much time has passed after having acute COVID-19. The follow-up time in these meta-analyses varied between 1 to 13 months. Even though most symptoms improve with time ⁴⁶, there is evidence in adult studies that suggests some symptoms can persist one year after COVID-19 diagnosis⁴⁷. It is important to understand which symptoms are associated with certain periods of time (e.g., 6 months, 12 months, 2 years).

The strength of this meta-analyses focuses on the large sample size⁴⁸ which helps identify the signs and symptoms present after acute SARS-CoV-2 infection. Further, there were some limitations such as the quality of the meta-analyses results depending on the quality of the studies included. Table 3 contains a list of all the methodological aspects that future studies need to consider. We can observe that all studies had a high probability of bias, including lack of standardized definitions, recall, selection, misclassification, nonresponse, and/or loss of follow-up. Additionally, the included studies have the limitations inherited in all observational studies, including bias due to residual and unmeasured confounding, and a high level of heterogeneity. To account for heterogeneity, we used a random-effects model⁴⁹. The differences between studies were likely due to differences in study designs, settings, populations, follow-up time, symptom ascertainment methods, inconsistent terminology, little details on stratification of pre-existing comorbidities, and prior receipt of COVID-19 therapeutics and vaccines. Only four studies mentioned what percentage of the population was already vaccinated^{15,16,20,28} (Table 3). It has been shown that vaccines reduce the risk of long-COVID in adults ⁵⁰. More studies are needed to analyze the relationship between vaccines in children with long COVID.

Study methodological Strength	N° of studies (N=21)	Prevalence (%)
COVID cases lab confirmed (PCR or antibody)	21	100
More than 100 COVID patients	14	66.66
Timing of COVID well specified	14	66.66
Long COVID defined >3 months	8	38.10

 Table 3. Study methodological strengths and limitations.

I I		
Point in time specific and well defined	10	42.11
Control added	8	31.6
Control group with negative antibody test	2	10.5
Clinical assessment (not self/ parent reported)	7	36.84
New symptoms on or after COVID	6	31.58
Specify if persistent symptom or if it is symptoms months after acute COVID	2	9.52
Exclude vaccinated / no vaccinated in sample	4	19.05
Duration (end) of symptoms specified	3	14.29
Validated questionnaires or Clinical evaluation for symptoms	5	23.81
Bias		
Low chance of Recall Bias	7	33.33
Low chance of Selection Bias	4	19.05
Low chance of Misclassification Bias	3	14.29
		14.20
Low chance of Nonresponse bias/ Loss of follow up	3	14.29
Low chance of Nonresponse bias/ Loss of follow up Stratifications	3	14.29
	3	14.29
Stratifications		
Stratifications Stratify by severity/only one severity	4	19.05

Stratify by vaccination status	0	0
--------------------------------	---	---

In our analyses, we included 2 pre-publication articles that are still not peer-reviewed ^{26,30}. The limitations of the study of Roessler *et al.* ³⁰ are inherited from all observational studies and are mentioned above. However its strengths are that it includes a large population (n=11,950), that physicians and psychotherapists validate the cases, and that they estimate the Incidence Rate Ratios (IRR), controlling for age, sex, and prevalent medical conditions by applying propensity score matching. They report that symptoms were statistically higher in the acute COVID-19 cohort (IRR=1.30) than in the controls without COVID-19. The study by Miller et al.²⁶ included children participating in VirusWatch, a household cohort in England and Wales that recruited households via postcards, social media, and SMS that had as an objective to study acute COVID-19. Long-COVID was defined as answering "YES" to the following question - "Have you presented any new symptoms that have lasted for four or more weeks even if these symptoms come and go and cannot be explained by something else?". Given the nature of the survey, it has a possibility of introducing bias to the results (recall bias, selection bias, misclassification bias, and nonresponse bias). The study does not present the frequencies for each symptom, and therefore it was not included in the meta-analyses of each symptom. We only included this study in the meta-analysis of overall long-COVID. The authors estimated a prevalence of 4.6%, which, compared to the other studies, is underestimated.

Future prospective studies should include a control cohort and stratify and/or adjust their results by age, sex, race, severity of acute COVID-19 infection paired with clinical evaluation, vaccination status, preexisting medical conditions, and, if possible, SARS-CoV-2 variant. If we had analyzed these types of factors separately, we would have been able to determine the variations in the prevalence of long-COVID. Retrospective studies using large population-based databases with historical controls and secondary data sources (e.g., claims and medical records) should also be used. The selection of controls will be difficult in the future because not all the cases are recorded in databases (e.g., home tests), tests can be false, negative, or positive, or children can be asymptomatic. Future studies' proposed control groups include a negative N protein antibody test without vaccination, a negative antibody test with vaccination, or historical cohorts that include children who have neither been vaccinated nor exposed to the virus.

CONCLUSION

Protective measures are essential to prevent long-COVID in children. We need to understand the long-COVID pathophysiology and symptomatology to support clinical management

22

systems, establish rehabilitation programs, and design guidelines and therapeutic research. Long-COVID represents a significant public health concern, and there are no guidelines to address its diagnosis and management. Our meta-analyses further support the importance of continuously monitoring the impact of long-COVID in minors and the need to include all variables and appropriate control cohorts in studies to better understand the real burden of pediatric long-COVID better.

Data availability.

All data relevant to the study are included in the article or uploaded as supplementary information. In addition, the datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

REFERENCES

- 1 Cucinotta, D. & Vanelli, M. WHO Declares COVID-19 a Pandemic. *Acta Biomed* **91**, 157-160, doi:10.23750/abm.v91i1.9397 (2020).
- 2 Agarwal, A. *et al.* A living WHO guideline on drugs for covid-19. *BMJ* **370**, m3379, doi:10.1136/bmj.m3379 (2020).
- 3 Chua, P. E. Y. *et al.* Epidemiological and clinical characteristics of non-severe and severe pediatric and adult COVID-19 patients across different geographical regions in the early phase of pandemic: a systematic review and meta-analysis of observational studies. *J Investig Med* **69**, 1287-1296, doi:10.1136/jim-2021-001858 (2021).
- 4 Kundu, A. *et al.* Clinical aspects and presumed etiology of multisystem inflammatory syndrome in children (MIS-C): A review. *Clin Epidemiol Glob Health* **14**, 100966, doi:10.1016/j.cegh.2022.100966 (2022).
- 5 Helms, J. *et al.* Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med* **382**, 2268-2270, doi:10.1056/NEJMc2008597 (2020).
- 6 Soriano, J. B. *et al.* A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*, doi:10.1016/S1473-3099(21)00703-9 (2021).
- 7 Clements, W., Joseph, T. & Koukounaras, J. UK NICE Guidelines for ÉVAR: Cost Implications for Post-COVID Australian Public Health. *Cardiovasc Intervent Radiol* **44**, 1286-1288, doi:10.1007/s00270-021-02832-2 (2021).
- 8 Nalbandian, A. *et al.* Post-acute COVID-19 syndrome. *Nat Med* **27**, 601-615, doi:10.1038/s41591-021-01283-z (2021).
- 9 Behnood, S. A. *et al.* Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. *J Infect* **84**, 158-170, doi:10.1016/j.jinf.2021.11.011 (2022).
- 10 Lopez-Leon, S. *et al.* More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep* **11**, 16144, doi:10.1038/s41598-021-95565-8 (2021).
- 11 Team, C. C.-R. Coronavirus Disease 2019 in Children United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep* **69**, 422-426, doi:10.15585/mmwr.mm6914e4 (2020).
- 12 Page, M. J. *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Rev Esp Cardiol (Engl Ed)* **74**, 790-799, doi:10.1016/j.rec.2021.07.010 (2021).
- 13 Barendregt, J. J., Doi, S. A., Lee, Y. Y., Norman, R. E. & Vos, T. Meta-analysis of prevalence. *J Epidemiol Community Health* **67**, 974-978, doi:10.1136/jech-2013-203104 (2013).
- 14 DerSimonian, R. & Laird, N. Meta-analysis in clinical trials revisited. *Contemp Clin Trials* **45**, 139-145, doi:10.1016/j.cct.2015.09.002 (2015).
- 15 Kikkenborg Berg, S. *et al.* Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. *Lancet Child Adolesc Health*, doi:10.1016/S2352-4642(22)00004-9 (2022).
- 16 Borch, L., Holm, M., Knudsen, M., Ellermann-Eriksen, S. & Hagstroem, S. Long COVID symptoms and duration in SARS-CoV-2 positive children a nationwide cohort study. *Eur J Pediatr*, doi:10.1007/s00431-021-04345-z (2022).
- 17 Roge, I. *et al.* Comparison of Persistent Symptoms After COVID-19 and Other Non-SARS-CoV-2 Infections in Children. *Front Pediatr* **9**, 752385, doi:10.3389/fped.2021.752385 (2021).
- 18 Smane, L., Roge, I., Pucuka, Z. & Pavare, J. Clinical features of pediatric post-acute COVID-19: a descriptive retrospective follow-up study. *Ital J Pediatr* **47**, 177, doi:10.1186/s13052-021-01127-z (2021).
- 19 Asadi-Pooya, A. A. *et al.* Long COVID in children and adolescents. *World J Pediatr* **17**, 495-499, doi:10.1007/s12519-021-00457-6 (2021).
- 20 Blankenburg, J. *et al.* Comparison of mental health outcomes in seropositive and seronegative adolescents during the COVID19 pandemic. *Sci Rep* **12**, 2246, doi:10.1038/s41598-022-06166-y (2022).

- 21 Buonsenso, D. *et al.* Preliminary evidence on long COVID in children. *Acta Paediatr* **110**, 2208-2211, doi:10.1111/apa.15870 (2021).
- 22 Erol, N., Alpinar, A., Erol, C., Sari, E. & Alkan, K. Intriguing new faces of Covid-19: persisting clinical symptoms and cardiac effects in children. *Cardiol Young*, 1-7, doi:10.1017/S1047951121003693 (2021).
- 23 Fink, T. T. *et al.* Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital. *Clinics (Sao Paulo)* **76**, e3511, doi:10.6061/clinics/2021/e3511 (2021).
- 24 Knoke L, S. A., Maier C, Eitner L, Lücke T, Brinkmann F. Pulmonary Function and Long-Term Respiratory Symptoms in Children and Adolescents After COVID-19. *Front. Pediatr.*, doi:doi.org/10.3389/fped.2022.851008 (2022).
- 25 Matteudi, T. *et al.* Clinical characteristics of paediatric COVID-19 patients followed for up to 13 months. *Acta Paediatr* **110**, 3331-3333, doi:10.1111/apa.16071 (2021).
- 26 Miller F, N. V., Navaratnam A, Shrotri M, Kovar J, Hayward AC, Fragaszy E, Aldridge RW, Hardelid P. Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales. *medRxiv* doi:05.28.21257602 (2021).
- 27 Molteni, E. *et al.* Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. *Lancet Child Adolesc Health* **5**, 708-718, doi:10.1016/S2352-4642(21)00198-X (2021).
- 28 Osmanov, I. M. *et al.* Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. *Eur Respir J* **59**, doi:10.1183/13993003.01341-2021 (2022).
- 29 Radtke, T., Ulyte, A., Puhan, M. A. & Kriemler, S. Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents. *JAMA*, doi:10.1001/jama.2021.11880 (2021).
- 30 Roessler M, T. F., Batram M, Jacob J, Loser F, Weidinger O, Wende D, Vivirito A, Toepfner N, Seifert M, Nagel O, König C, Jucknewitz R, Armann JP, Berner R, Treskova-Schwarzbach M, Hertle D, Scholz S, Stern S, Ballesteros P, Baßler S, Bertele B, Repschläger U, Richter N, Riederer C, Sobik F, Schramm A, Schulte C, Wieler L, Walker J, Scheidt-Nave C, Schmitt J. Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19. *medRxiv*, doi:10.21.21265133 (2021).
- 31 Rusetsky, Y. *et al.* Smell Status in Children Infected with SARS-CoV-2. *Laryngoscope* **131**, E2475-E2480, doi:10.1002/lary.29403 (2021).
- 32 Say, D. *et al.* Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. *Lancet Child Adolesc Health* **5**, e22-e23, doi:10.1016/S2352-4642(21)00124-3 (2021).
- 33 Stephenson, T. *et al.* Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. *Lancet Child Adolesc Health* **6**, 230-239, doi:10.1016/S2352-4642(22)00022-0 (2022).
- 34 Sterky, E. *et al.* Persistent symptoms in Swedish children after hospitalisation due to COVID-19. *Acta Paediatr* **110**, 2578-2580, doi:10.1111/apa.15999 (2021).
- 35 Zavala, M., Ireland, G., Amin-Chowdhury, Z., Ramsay, M. E. & Ladhani, S. N. Acute and persistent symptoms in children with PCR-confirmed SARS-CoV-2 infection compared to test-negative children in England: active, prospective, national surveillance. *Clin Infect Dis*, doi:10.1093/cid/ciab991 (2021).
- 36 Molteni, E. *et al.* Long COVID in children Authors' reply. *Lancet Child Adolesc Health* **6**, e3, doi:10.1016/S2352-4642(21)00344-8 (2022).
- 37 Ravens-Sieberer, U. *et al.* [Mental health and psychological burden of children and adolescents during the first wave of the COVID-19 pandemic-results of the COPSY study]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **64**, 1512-1521, doi:10.1007/s00103-021-03291-3 (2021).

- 38 Solmi, M. *et al.* Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times Children and Adolescents (COH-FIT-C&A). *J Affect Disord* **299**, 367-376, doi:10.1016/j.jad.2021.09.090 (2022).
- 39 Dotan, A., David, P., Arnheim, D. & Shoenfeld, Y. The autonomic aspects of the post-COVID19 syndrome. *Autoimmun Rev* **21**, 103071, doi:10.1016/j.autrev.2022.103071 (2022).
- 40 Evans, S. S., Repasky, E. A. & Fisher, D. T. Fever and the thermal regulation of immunity: the immune system feels the heat. *Nat Rev Immunol* **15**, 335-349, doi:10.1038/nri3843 (2015).
- 41 Atzeni, F. *et al.* One year in review 2019: fibromyalgia. *Clin Exp Rheumatol* **37 Suppl 116**, 3-10 (2019).
- 42 Caronna, E. & Pozo-Rosich, P. Headache during COVID-19: Lessons for all, implications for the International Classification of Headache Disorders. *Headache* **61**, 385-386, doi:10.1111/head.14059 (2021).
- 43 Barizien, N. *et al.* Clinical characterization of dysautonomia in long COVID-19 patients. *Sci Rep* **11**, 14042, doi:10.1038/s41598-021-93546-5 (2021).
- 44 Sharif, K. *et al.* On chronic fatigue syndrome and nosological categories. *Clin Rheumatol* **37**, 1161-1170, doi:10.1007/s10067-018-4009-2 (2018).
- 45 Brodin, P. *et al.* Variation in the human immune system is largely driven by nonheritable influences. *Cell* **160**, 37-47, doi:10.1016/j.cell.2014.12.020 (2015).
- 46 Seessle, J. *et al.* Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. *Clin Infect Dis*, doi:10.1093/cid/ciab611 (2021).
- 47 Fumagalli, C. *et al.* Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study. *Eur J Intern Med*, doi:10.1016/j.ejim.2021.11.018 (2021).
- 48 Finckh, A. & Tramer, M. R. Primer: strengths and weaknesses of meta-analysis. *Nat Clin Pract Rheumatol* **4**, 146-152, doi:10.1038/ncprheum0732 (2008).
- 49 Cumpston, M. *et al.* Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev* **10**, ED000142, doi:10.1002/14651858.ED000142 (2019).
- 50 Kuodi P, G. Y., Zayyad H, Wertheim O, Wiegler KB, Jabal KA, Dror AA, Nazzal S, Glikman D and Edelstein M. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. *medRxiv*, doi:01.05.22268800 (2022).

Abbreviations

CI: Credible interval COVID-19: Coronavirus disease 2019 CSS: cross-sectional study DM: diabetes mellitus QCed: Quality-Controlled IRR: Incidence Rate Ratios NICE: National Institute for Health and Care Excellence MIS-C: multisystem inflammatory syndrome ORs: Odds Ratios PCS: prospective cohort study PRISMA: Preferred Items for Systematic Reviews and Meta-Analyses RCS: retrospective cohort study rt-PCR: real-time reverse transcription-polymerase chain reaction SARS-CoV-2: severe acute respiratory syndrome coronavirus 2 PASC: post-acute sequelae of SARS-CoV-2

Acknowledgments

Figure 2 was created by S.V. using Biorender.com. The authors are indebted to Dr. Gillian Hamilton for editing.

Funding

This article was funded by Houston Methodist Research Institute (S.V.).

Contributions. A.C., C.A., P.R., and R.S. extracted data. S.L.L. performed the statistical analyses, T.W.O. performed the QC of the results. T.W.O., C.P., R.S., P.R., and S.V. performed the literature search, collected the data, wrote the manuscript, and made edits. S.L.L. and S.V. were mainly responsible for interpreting the data and preparing the final version. S.V. created the figures. All authors provided critical feedback and contributed to the final manuscript. Correspondence and requests for materials should be addressed to S.V.

Ethics declarations

Competing interests

The authors are solely responsible for all content, and funders played no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.

S.L.L. is an employee of Novartis Pharmaceutical Company; the statements presented in the paper do not necessarily represent the position of the company. The remaining authors have no competing interests to declare.

FIGURE LEGENDS


Figure 1. PRISMA diagram with exclusion criteria. Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) screening process flow. Out of 8,373 identified studies and after applying the inclusion and exclusion criteria, 21 studies were included in the quantitative synthesis.

Figure 2. The pooled prevalence of long-COVID by symptoms in children and adolescents. Meta-analyses revealed that the prevalence of more than 40 long-COVID symptoms in children and adolescents. The presence of one or more symptoms following a SARS-CoV-2 infection was 25.24%.

Figure 3. Forest Plot of pooled prevalence of long-COVID overall in children and adolescents.

Figure 4. Pooled Odds Ratios with 95% CI in cases vs. controls. The size of each box indicates the effect of each study by symptom assigned using the Odds ratios (95% CI) by age and domain.





Records identified through Embase (n = 928)

Out of scope (n = 8,305)


Reports excluded: (n = 47)Reasons:

- Protocol, review, commentary (n = 11)
- Includes patients older than 18 (n = 4)
- Less than 30 patients/case reports (n = 11)
- No long-COVID (acute / MISC) (n = 10)
- No denominator (n = 5)
- Data combined with adults (n = 3)
- Survey to paediatrics (n = 2)
- Abstract (n = 1)




Long-COVID in children and adolescents

Neuropsychiatric (%) • Mood (16.50) (sad, tense, angry, anxiety, depression) • Fatigue (9.66) • Sleep disorder (8.42) (insomnia, hypersomnia, poor sleep quality) Headache (7.84) • Cognition (6.27) (confusion, impaired concentration, learning difficulties, memory loss)





8.00 - 17.00%

4.00 - 7.99%



	Sore throat (2.47)									
_	Chest tightness 2.45									
	Variations in heart rate (2.29)									
	• Palpitations 1.27									
	Dermatologic/Teguments (%									
	• Hyperhidrosis (4.66)									
	• Dermatologic 2.61 (dry skin,									
	itchy skin, rashes, hives)									
	• Hair loss 1.17									
	Others (%)									
	o Loss of appetite (6.07)									
	• Altered smell (5.60) (phantom smell,									
	hyposmia, anosmia, hyperosmia)									
	OBODY weight changes (3.99)									
	o Myalgia/arthralgia (3.76)									
	o Altered taste 3.65									
	o Otalgia (3.41) (tinnitus, earache or vertigo)									
	Ophtalmologic (3.00) (conjuntivitis, dry									
	eyes, problems seeing/blurred vision,									
	photophobia, pain)									
	o Swollen lymph nodes (2.58)									
	O Dysphonia (1.89)									
	• Fever (1.87)									
	OMUSCULOSKELETAL OTHER 1.72									
	O Changes in menstruation (1.27)									
	OUrinary symptoms 0.63									
	O Dysphagia 0 46									





5% C	:1)	% Weight
D.32,	0.58)	5.8
0.25,	0.26)	6.6
D.28,	0.44)	6.2
0.29,	0.46)	6.2
0.30,	0.57)	5.7
0.17,	0.38)	5.9
D.11,	0.24)	6.2
0.02,	0.08)	6.3
0.01,	0.03)	6.6
D.21,	0.28)	6.5
0.01,	0.08)	6.2
0.20,	0.21)	6.6
0.58,	0.70)	6.4
0.04,	0.13)	6.3
D.65,	0.68)	6.6
D.12,	0.34)	5.7
D.18.	0.33)	100.0

	Odds Ratio	Odds Ratio
Study or Subgroup	Random, 95% Cl	Random, 95% Cl
Mood		
Kikkenborg Berg Age 15-18 (vs. no postive test)	0.82 [0.74, 0.91]	
Roge age 0-18 (vs other infections)	16.00 [4.60, 55.65]	
Zavala age 0-16 (vs PCR neg symptomatic)	3.94 [1.16, 13.38]	
Subtotal (95% CI)	3.46 [0.51, 23.27]	
Heterogeneity: Tau ² = 2.59 ; Chi ² = 27.80 , df = 2 (P <	0.00001); l ² = 93%	
Test for overall effect: Z = 1.28 (P = 0.20)		
Fatigue		
Kikkenborg Berg Age 15-18 (vs. no postive test)	1.06 [0.98, 1.15]	
Knoke age 5-18(vs no antibodies /other infecction)	3.19 [0.70, 14.54]	
Roge age 0-18 (vs other infections)	8.70 [2.50, 30.28]	
Subtotal (95% CI)	2.79 [0.66, 11.75]	
Heterogeneity: Tau ² = 1.32; Chi ² = 12.89, df = 2 (P = $\frac{1}{2}$	0.002): $l^2 = 84\%$	
Test for overall effect: $Z = 1.40$ (P = 0.16)		
Headache		
Kikkenborg Berg Age 15-18 (vs. no postive test)	1.22 [1.10, 1.35]	
Knoke age 5-18(vs no antibodies /other infecction)	1.44 [0.38, 5.46]	
Roge age 0-18 (vs other infections)	12.90 [1.70, 97.89]	
Subtotal (95% CI)	1.95 [0.69, 5.52]	
Heterogeneity: Tau ² = 0.53; Chi ² = 5.24, df = 2 (P = 0	.07); l² = 62%	
Test for overall effect: Z = 1.25 (P = 0.21)		

Dyspnea

Kikkenborg Berg Age 15-18 (vs. no postive test) 2.70 [2.31, 3.16] Knoke age 5-18(vs no antibodies /other infecction) 1.63 [0.15, 17.71] Roge age 0-18 (vs other infections) 2.10 [0.20, 22.05] Subtotal (95% CI) 2.69 [2.30, 3.14] Heterogeneity: Tau² = 0.00; Chi² = 0.21, df = 2 (P = 0.90); l² = 0%Test for overall effect: Z = 12.49 (P < 0.00001) **Concentration problems** Kikkenborg Berg Age 15-18 (vs. no postive test) 1.04 [0.97, 1.12] Roge age 0-18 (vs other infections) 13.60 [1.70, 108.81] 3.02 [0.25, 36.19] Subtotal (95% CI) Heterogeneity: Tau² = 2.74; Chi² = 5.86, df = 1 (P = 0.02); l² = 83%Test for overall effect: Z = 0.87 (P = 0.38) Anosmia/ Ageusia Roge age 0-18 (vs other infections) 11.20 [1.40, 89.61] Zavala age 0-16 (vs PCR neg symptomatic) 10.20 [1.31, 79.41] 10.68 [2.48, 46.03] Subtotal (95% CI) Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.95); l² = 0%Test for overall effect: Z = 3.18 (P = 0.001) Loss of appetite Kikkenborg Berg Age 15-18 (vs. no postive test) 1.15 [1.02, 1.30] Roge age 0-18 (vs other infections) 2.50 [0.90, 6.95] Subtotal (95% CI) 1.43 [0.72, 2.82]

Heterogeneity: Tau² = 0.16; Chi² = 2.19, df = 1 (P = 0.14); l² = 54% Test for overall effect: Z = 1.02 (P = 0.31)

Rhinitis

Knoke age 5-18(vs no antibodies /other infecction)0.14 [0.03, 0.65]Roge age 0-18 (vs other infections)2.60 [1.30, 5.20]Subtotal (95% Cl)0.66 [0.04, 11.44]Heterogeneity: Tau² = 3.90; Chi² = 11.49, df = 1 (P = 0.0007); l² = 91%Test for overall effect: Z = 0.29 (P = 0.77)

Myalgia/ arthralgia

Kikkenborg Berg Age 15-18 (vs. no postive test)1.09 [0.91, 1.31]Knoke age 5-18(vs no antibodies /other infecction)1.24 [0.33, 4.66]Subtotal (95% Cl)1.09 [0.91, 1.31]Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.85); l² = 0%

Test for overall effect: Z = 0.97 (P = 0.33)

Cough

 Kikkenborg Berg Age 15-18 (vs. no postive test)
 1.63 [1.43, 1.86]

 Knoke age 5-18(vs no antibodies /other infecction)
 0.24 [0.06, 0.96]

 Roge age 0-18 (vs other infections)
 1.90 [0.90, 4.01]

 Subtotal (95% Cl)
 1.20 [0.55, 2.58]

Heterogeneity: Tau² = 0.32; Chi² = 7.46, df = 2 (P = 0.02); l² = 73% Test for overall effect: Z = 0.45 (P = 0.65)

Fever

Kikkenborg Berg Age 15-18 (vs. no postive test)	1.53 [0.74, 3.16]		
Knoke age 5-18(vs no antibodies /other infecction)	2.69 [0.67, 10.80]		
Roge age 0-18 (vs other infections)	4.00 [1.40, 11.43]		
Subtotal (95% CI)	2.23 [1.22, 4.07]		
Heterogeneity: Tau ² = 0.04; Chi ² = 2.28, df = 2 (P = $\frac{1}{2}$			
Test for overall effect: $Z = 2.61$ (P = 0.009)			
Sore throat			
Kikkenborg Berg Age 15-18 (vs. no postive test)	1.59 [1.21, 2.09]		
Knoke age 5-18(vs no antibodies /other infecction)	0.44 [0.12, 1.61]		
Roge age 0-18 (vs other infections)	3.50 [0.70, 17.50]		
Subtotal (95% CI)	1.34 [0.54, 3.27]		
Heterogeneity: Tau ² = 0.37; Chi ² = 4.62, df = 2 (P = 0.10); l ² = 57%			
which the provided by peer review is the action funder, and has prevented by the operation of the prevented by peer review in			
Nausea/ Vomiting			
	1 00 00 1 201		
Kikkenborg Berg Age 15-18 (vs. no postive test)	1.09 [0.92, 1.29]		
Roge age 0-18 (vs other infections)	6.20 [0.60, 64.06]		
Subtotal (95% CI)	1.73 [0.38, 7.81]		
Heterogeneity: Tau ² = 0.80; Chi ² = 2.12, df = 1 (P = 0.15); l ² = 53%			
Test for overall effect: Z = 0.71 (P = 0.47)			

